Technology Bundle ID
TAB-3106

Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use

Linked ID
E-136-2013-0
Lead Inventors
Lorena Garaicoechea (Instituto Nacional De Tecnologia Agropecuaria (INTA))
Co-Inventors
Andrea Aguilar (Instituto Nacional De Tecnologia Agropecuaria (INTA))
Gladys Parreno (Instituto Nacional de Technologia Agropecuaria (INTA))
Karin Bok (NIAID)
Lisbeth Kim Green (NIAID)
Marina Bok (Instituto Nacional De Tecnologia Agropecuaria (INTA))
Stanislav Sosnovtsev (NIAID)
Therapeutic Areas
Infectious Disease
ICs
NIAID
Vaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims isolated VHH monoclonal antibodies that specifically bind to a Norovirus polypeptide. Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa (“nanobodies”) with several advantages over conventional antibodies. The antibodies that were derived from llamas showed strong neutralizing activity against Norovirus in in vitro assays. These nanobodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections, and may be potentially utilized in vaccine research.
Commercial Applications
  • Therapeutics
  • Diagnostics
  • Vaccine research
Competitive Advantages
  • Ease of manufacture
  • Potent neutralizing activity
  • Potential cross-reactivity
  • Low-cost therapeutics/immunoprophylaxis

Request More Info

Licensing Contact: